Irene Margaret Vavasour1, Poljanka Johnson2, Shawna Abel3, Stephen Ristow3, Jared Splinter3, Cornelia Laule1,4,5,6, Roger Tam1, David KB Li1, Nathalie Ackermans3, Alice J Schabas3, Jillian Chan3, Helen Cross3, Ana-Luiza Sayao3, Virginia Devonshire3, Robert Carruthers3, Anthony Traboulsee3, and Shannon H Kolind1,3,4,6
1Radiology, University of British Columbia, Vancouver, BC, Canada, 2Neuroscience, University of British Columbia, Vancouver, BC, Canada, 3Medicine, University of British Columbia, Vancouver, BC, Canada, 4Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada, 5Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 6International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada
1Radiology, University of British Columbia, Vancouver, BC, Canada, 2Neuroscience, University of British Columbia, Vancouver, BC, Canada, 3Medicine, University of British Columbia, Vancouver, BC, Canada, 4Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada, 5Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 6International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada
Using multi-echo T2 relaxation, a decrease in mean myelin
water fraction over two years was detected in the normal appearing white matter
of relapsing-remitting and progressive multiple sclerosis participants.
Figure 4: Percentage change over 2 years in mean myelin water
fraction (MWF) for each
participant
divided
into participant subtype (healthy control (HC), relapsing remitting multiple
sclerosis (RRMS), progressive multiple sclerosis (PMS)).
The last bar (in red) is the mean over the participants.
Figure 2: Mean myelin water fraction (±standard
deviation) at baseline (B) and follow-up (FU),
absolute change in MWF over 2 years, percent MWF change over 2 years (%) and annual rate of MWF percent change divided into
participant subtype
(healthy control (HC), relapsing remitting multiple sclerosis (RRMS),
progressive multiple sclerosis (PMS)). Volumes are taken at baseline. Significant differences between baseline
and follow-up are denoted in pink with *p<0.01, ***p<0.0001.
